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STUDY QUESTION: Which clinical and ethical aspects of preimplantation genetic testing for monogenic disorders or structural rearrange-
ments (PGT-M, PGT-SR) should be considered when accepting requests and counselling couples for PGT when applied for more than one
condition (combination-PGT; cPGT-M/SR)?
SUMMARY ANSWER: cPGT is a feasible extension of the practice of PGT-M/SR that may require adapting the criteria many countries have
in place with regard to indications-setting for PGT-M/SR, while leading to complex choices that require timely counselling and information.
WHAT IS KNOWN ALREADY: Although PGT-M/SR is usually performed to prevent transmission of one disorder, requests for PGT-
M/SR for more than one condition (cPGT-M/SR) are becoming less exceptional. However, knowledge about implications for a responsible
application of such treatments is lacking.
STUDY DESIGN, SIZE, DURATION: Retrospective review of all (40) PGT-M/SR applications concerning more than one genetic condition
over the period 1995–2018 in the files of the Dutch national PGT centre. This comprises all relevant national data since the start of PGT in the
Netherlands.
PARTICIPANTS/MATERIALS, SETTING AND METHODS: Data regarding cPGT-M/SR cases were collected by means of reviewing
medical files of couples applying for cPGT-M/SR. Ethical challenges arising with cPGT-M/SR were explored against the background of PGT-
M/SR regulations in several European countries, as well as of relevant ESHRE-guidance regarding both indications-setting and transfer-decisions.
MAIN RESULTS AND THE ROLE OF CHANCE: We report 40 couples applying for cPGT-M/SR of which 16 couples started their
IVF treatment. Together they underwent 39 IVF cycles leading to the birth of five healthy children. Of the couples applying for cPGT, 45%
differentiated between a primary and secondary condition in terms of perceived severity. In the light of an altered balance of benefits and
drawbacks, we argue the ‘high risk of a serious condition’ standard that many countries uphold as governing indications-setting, should be
lowered for secondary conditions in couples who already have an indication for PGT-M/SR. As a consequence of cPGT, professionals will
more often be confronted with requests for transferring embryos known to be affected with a condition that they were tested for. In line with
ESHRE guidance, such transfers may well be acceptable, on the condition of avoiding a high risk of a child with a seriously diminished quality
of life.
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LIMITATIONS, REASONS FOR CAUTION: We are the first to give an overview of cPGT-M/SR treatments. Retrospective analysis was
performed using national data, possibly not reflecting current trends worldwide.
WIDER IMPLICATIONS OF THE FINDINGS: Our observations have led to recommendations for cPGT-M/SR that may add to centre
policy making and to the formulation of professional guidelines. Given that the introduction of generic methods for genomic analysis in PGT
will regularly yield incidental findings leading to transfer requests with these same challenges, the importance of our discussion exceeds the
present discussion of cPGT.
STUDY FUNDING/COMPETING INTEREST(S): The research for this publication was funded by the Dutch Organization for Health
Research and Development (ZonMw), project number: 141111002 (Long term safety, quality and ethics of Preimplantation Genetic Diagnosis).
None of the authors has any competing interests to declare.
Key words: preimplantation genetic testing/combination PGT/ethics/indications/transfer decisions
Introduction
Over the past decades, preimplantation genetic testing for mono-
genic disorders (PGT-M) or structural rearrangements (PGT-SR) has
become an established technique allowing couples at high risk of having
affected offspring to avoid the birth of a child with a serious genetic
disorder or of losing the pregnancy as a result of an unbalanced
chromosomal abnormality. PGT as offered for these indications (PGT-
M/SR) comprises an in vitro fertilization (IVF)-treatment combined
with a blastomere biopsy at the cleavage stage or trophectoderm
(TE) biopsy at the blastocyst stage of the in vitro embryo. The cell
or cells thus obtained are tested for the relevant mutation(s) and/or
chromosomal anomalies. This then allows for the selective transfer of
embryos in which the targeted genetic condition is absent, thereby
enabling at risk couples to reproduce with confidence (Harton et al.,
2011). Although usually performed to avoid the transmission of a
single disease, PGT-M/SR allows for simultaneous testing for more
disorders. Nowadays, it is no longer rare for centres to be con-
fronted with applicants asking for such ‘combination PGT’ (cPGT-
M/SR). Two case reports describe cPGT-M for Tay–Sachs and Gaucher
disease and a cPGT-M/SR for a reciprocal translocation and alfa-
thalassemia (Altarescu et al., 2007; Lee et al., 2014). Kuliev et al.
(2014) listed a small series of cPGT-M treatments including combi-
nations of single-gene disorders like Charcot–Marie–Tooth and Fabry
disease; HBOC (hereditary breast and ovarian cancer) and SMA (spinal
muscular atrophy) and HBOC and MEN1 (multiple endocrine neo-
plasms type 1). Rechitsky et al. (2013) reported 11 cycles of com-
bined testing for cystic fibrosis (CF) mutations and another monogenic
disorder.
Several factors may have led to a growing number of requests for
cPGT-M/SR, including an increased familiarity with the role of genetics
in disease, and a greater awareness of personal reproductive risks as a
result of more frequent genomic testing in families. The possible future
introduction of a routine offer to the general population of expanded
preconception carrier screening for recessive disorders may further
add to this effect (Henneman et al., 2016; Sallevelt et al., 2017). Finally,
possibilities to diagnose genetic disorders at a single-cell level are
expanding. For instance, comprehensive methods such as genome wide
single nucleotide polymorphism (SNP) haplotyping (karyomapping) or
next generation sequencing (NGS)-based techniques (Natesan et al.,
2014; Zamani et al., 2015) enable simultaneous testing for multiple or
even an unlimited number of genetic disorders without the need for
extensive customization of PGT protocols.
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Materials and Methods
We retrospectively reviewed all PGT-M/SR applications concerning
more than one genetic condition in the files of the Dutch national
PGT centre at the Maastricht University Medical Centre since the
start of PGT in the Netherlands (1995–2018). All data were col-
lected prospectively. This review was limited to applications involving
monogenic/mitochondrial or structural chromosomal abnormalities
for which the applicants were known to be at risk, thus excluding PGT
for ‘de novo’ aneuploidy (i.e. PGT-A) or HLA-typing. Data concerning
applications and counselling, protocol development, IVF-treatment,
results of PGT-analysis, and obstetric outcome were evaluated. Ethical
challenges arising with cPGT-M/SR were explored against the back-
ground of PGT-M/SR regulations in several European countries, as well
as of relevant ESHRE-guidance regarding both indications-setting and
transfer-decisions.
Results
In this section, we present both our clinical data and the findings of our
ethical exploration with regard to how cPGT/M-SR relates to criteria
for indications-setting and transfer-decisions.
Clinical data
Applications and counselling
We reviewed requests for cPGT-M/SR from 40 couples (Table I).
These involved either two structural chromosomal anomalies (n = 10),
two monogenic disorders (n = 7), or combinations of both (also includ-
ing mitochondrial diseases) (n = 23). Three out of four couples apply-
ing for cPGT for two autosomal recessive diseases were consan-
guineous.
When asked, eighteen couples (45%) identified a ‘primary’ and
‘secondary’ condition in terms of perceived severity. Neurofibro-
matosis type 1 (NF1) was perceived as the primary condition for all
three couples requesting cPGT for NF1. HBOC was perceived as the
secondary indication for five out of seven couples asking for cPGT.
CF was perceived as the secondary condition in three out of four
requests involving this disease. Twenty-two couples (55%) perceived
both conditions for which they requested cPGT as equally severe or
could not make a differentiation because of the nature of the disorders
(for example two structural chromosomal anomalies, both with a high
risk of miscarriage) (Table I).
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Table I Indications for combination PGD according to mode of inheritance (n = 40) and started cycles (n = 16).
Couple number AD AR C XL M
AD (n = 20)
.......................................................................................................................................................................................
1
2
3
NF 1 Aniridia∗
HME 1∗
Myoclonus dystrophy
- - - -
.......................................................................................................................................................................................
4
5
6
DM 1 - - Translocation (n=2)
22q11deletion∗
- -
.......................................................................................................................................................................................
7
8
9
10
11
12
HBOC (BRCA2) Retinoblastoma∗
Hereditary diffuse gastric cancer
Deafness type 22
-
Lujan–Fryns syndrome∗
Duchenne muscular dystrophy
MELAS∗
.......................................................................................................................................................................................
13 HBOC (BRCA 1) Noonan syndrome - - - -
.......................................................................................................................................................................................
14 Peutz–Jeghers syndrome Porencephaly∗ - - - -
.......................................................................................................................................................................................
15 Familial paraganglioma Saethre Chotzen
syndrome
- - - -
.......................................................................................................................................................................................
16 Ehlers–Danlos type VI - MPS VII - - -
.......................................................................................................................................................................................
17 SCA 6 - CF - - -
.......................................................................................................................................................................................
18
19
FAP - PAE
Translocation
- -
.......................................................................................................................................................................................
20 HME 1 - - - Retinitis pigmentosa∗ -
.......................................................................................................................................................................................
AR (n = 9 ) - - - - -
.......................................................................................................................................................................................
21
22
23
CF Zellweger
Translocation
Fragile X syndrome
-
24 GM1 gangliosidose MADD - - -
25 AOA 1 SMA 1∗ - - -
26 Cockayne syndrome - Limb Girdle
Muscular
Dystrophy 2C
- - -
27 Sickle cell disease - Translocation - -
28 Pompe disease - Translocation - -
29 Alpers syndrome - - - MELAS∗
.......................................................................................................................................................................................
C (n = 11) - - - -
.......................................................................................................................................................................................
30
-
39
40
Translocation - Translocation
(n = 10)∗∗∗∗∗∗
Fragile X syndrome
-
Bold indicates primary condition as indicated by the couple (n = 18 (45%); see text for explanation); ∗ indicates started cycles.
Conditions are listed according to mode of inheritance (rows 1–20 combination with AD condition; rows 21–29 combination with AR condition excluding AD conditions; rows 30–40
combination with chromosomal anomaly excluding AD and AR conditions.)
AD, autosomal dominant; AR, autosomal recessive; XL, X-linked; C, chromosomal; M, mitochondrial; s. indicates ‘syndrome’; XL indicates ‘X-Linked’; d. indicates ‘disease’ NF1,
neurofibromatosis type 1; HME 1, hereditary multiple exostoses type 1; DM 1, myotonic dystrophy type 1; HBOC, hereditary breast and ovarium cancer; BRCA, breast cancer;
MELAS, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; DFNB 22, DeaFNess – autosomal recessive type 2; MPSV II, mucopolysaccharidosis type 7; SCA
6, spino cerebellar ataxia type 6; CF, cystic fibrosis; FAP, familial adenomatous polyposis; PAE, pyridoxine dependent epilepsy; MADD, multiple acyl CoA dehydrogenase deficiency;
AOA1, ataxia-oculomotor apraxia type 1; SMA 1, spinal muscular atrophy type 1.
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Figure 1 Outcome embryo analysis in cPGT-M/SR (n=187).
Number of embryos (% of total in category) not affected for both
conditions (lighter shade - top) and affected for one or both conditions
(darker shade - bottom), for two autosomal dominant conditions
(column 1), autosomal recessive conditions (column 2), chromosomal
anomalies (column 3), other combinations of conditions (column 4),
and the total of embryos analyzed (column 5).
Twenty-one couples (52%) proceeded with cPGT treatment. Com-
binations of disorders comprised two chromosomal abnormalities
(n = 6), monogenic disorders (n = 8), or a combination of the
above and mitochondrial diseases (n = 7). Five of these couples
are still awaiting protocol development. Nineteen couples (48%)
refrained after intake. Reasons to refrain were low chance of success
(n = 4), opting for PGT for one disorder (n = 3), preference for
prenatal testing (PNT) (n = 3), medical contra-indication for IVF-
treatment (n = 2), ending of the relationship (n = 2), PGT-treatment
in a hospital abroad (n = 2), treatment not possible because of
technical reasons (n = 1), religion (n = 1), and spontaneous pregnancy
(n = 1).
cPGT-M/SR treatments
For 16 couples, treatment protocols were developed; six for combi-
nations of chromosomal anomalies by either FISH or array compara-
tive genomic hybridization (CGH) analysis, seven for two monogenic
disorders by marker and/or mutation analysis, two for a monogenic
and a mitochondrial disorder by quantative analysis and one for a
combination of a monogenic disorder and a chromosomal anomaly
(Table II). All treatment protocols were based on blastomere biopsies
(Day 3).
The 16 couples underwent 39 cycles and 187 embryos were analyzed
(Fig. 1). Of these, 47 (47/187 = 25%) displayed the wild-type or
normal/balanced genotype of both tested disorders and thus were
genetically suitable for transfer. These concerned 15 out of 52 embryos
analyzed for two autosomal dominant disorders (15/52=29%), 9
embryos out of 17 tested for two autosomal recessive disorders
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(9/17 = 53%), 10 embryos of 77 analyzed for two chromosomal
anomalies (10/77 = 13%) and 13 of the 23 embryos analyzed for other
combinations than mentioned above (13/23 = 57%). Of the other 140
analyzed embryos, 46 were free from both conditions tested for and 59
embryos were affected by both. Of 35 embryos no conclusive results
could be obtained.
Thirteen couples underwent one or more embryo transfer(s). A
fresh embryo transfer was performed in 21/39 (54%) of the cPGT
cycles. An additional seven frozen embryo transfers were performed,
adding up to a total of 28 transfers (28/39 cycles = 72%). Three double
embryo transfers were performed (3/28 = 11%). In three consecutive
PGT cycles of couple no. 14, no embryos free from both disorders
were available. Although in the counselling before treatment, they
clearly stated that they opted for exclusion of both disorders, the
couple requested transfer of an embryo affected with Peutz–Jeghers
syndrome in all three cycles. No pregnancy was achieved.
Six single embryo transfers (four fresh and two frozen) resulted
in a positive HCG test (6/28 = 21%). In four of these cases, two
blastomeres were biopsied (Table II). One pregnancy ended in a mis-
carriage at 6+4 weeks gestational age, genotype unknown. Five children
were born, three boys (Table II no. 1, 9, 20) and two girls (Table II no.
9, 37). Prenatal or postnatal testing to confirm cPGT diagnosis was
performed for two couples (no. 9 and no. 37). In both cases, the cPGT
results were confirmed. Couple 9 obtained two healthy PGT children,
one from a fresh transfer and the second resulting from a frozen cycle.
Couple no. 10 requested analysis for only the MELAS (mitochon-
drial encephalopathy, lactic acidosis, and stroke-like episodes) muta-
tion after two unsuccessful PGT treatments for both the MELAS
and the BRCA2 mutation. This third cycle resulted in an ongoing
bpregnancy.
Ethical exploration
Indications setting for cPGT-M/SR
In countries where PGT-M/SR is available, its lawful application is often
limited to couples with a ‘significant’ or ‘high’ risk of transmitting a
‘serious’ genetic disorder to their offspring (see Fig. 2). In this paper,
we will refer to this as ‘the high risk of a serious disorder’ standard. The
reasoning behind this requirement often remains unspecified. How-
ever, ESHRE’s Task Force Ethics & Law has suggested that the standard
should be understood as reflecting the ‘proportionality’ of PGT-M/SR
(De Wert et al., 2014). This notion refers to the balance between the
benefits that PGT may have for the applicants on the one hand and the
various aspects that make it a morally sensitive technology on the other.
If this interpretation is correct, then a significant change on the ‘issues
and concerns’ side of the proportionality balance may lead to a differ-
ent range of acceptable indications (De Wert et al., 2014). As argued
by the Task Force, there are two situations where this would apply. One
is PGT-M/SR for applicants with a fertility problem that gives them a
separate indication for IVF or intracytoplasmatic sperm injection (ICSI).
The second is where people have an indication for PGT-M/SR and
want to add testing for a further disorder for which they are also at
risk. In both situations, a significant part of the burdens and (moral)
costs have already been taken account of, either with respect to IVF or
ICSI as fertility treatment, or for doing PGT for the primary disorder.
Adding PGT-M/SR to fertility treatment or doing PGT-M/SR for a
further condition could therefore be considered also for lower risk or
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Table II Combination PGD treatments according to method of analysis (n = 16).
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FISH (n=3)
30 46, XY, t(4;7)(q21.3;q21.2) 46, XX, t(4;22)(p11;p11.2) 1 Overstim. cancel
2 Poor response cancel
3 4 1 0
4 Poor response cancel
31 45,XY,der(14;21)(q10;q10) 45,XX,der(13:14)(q10;q10) 1 Poor response cancel
2 6 1 0
3 Follic. <8
33 46,XX,t(1;2) (q44;q33) 45,XYder(13;14)(q10;q10) 1 Follic. <8
2 Follic. <8
3 4 2 0
4 Follic. <8
A CGH (n = 3)
35 45,XX,t(3;4)(q22;q31.3) 45,XX,der(13;14)(q10;q10) 1 7 1 0
2 7 1 1 F 1 -
3 9 1 1 F 1 -
4 5 1 2 F 2 -
37 45,XX,der(13;14)(q10;q10) 46,XY,t(6;14)(q25.3;q24.3) 1 9 1 2 F 1 + Healthy daughter
NIPT normal
38 45,XX,der(14;22)(q10;q10) 46,XY,t(3;16)(q29;q24) 1 24 1 4 F 1 -
PCR - 1 protocol for the two conditions (n = 4)
2 NF 1 Markers + mutation HME 1 Markers 1 5 1 1 F 1 -
2 10 1 3 F 1 + Miscarriage
6+4 w AD
3 8 1 5 F 1 -
C 1 -
7 HBOC Markers + mutation Retino-blastoma Markers 1 3 1 1 F 1 -
2 4 1 0
3 7 1 1 F 1 -
14 Peuts–Jeghers
syndrome
Markers Porencephaly Markers + mutation 1 3 1 0 F 1 -
2 4 1 0 F 1 -
3 6 1 0 F 1 -
25 AOA 1 Markers + mutation SMA 1 Markers + mutation 1 5 1 1 F 1 -
2 23 1 5 F 1 -
C 1 -
C 1 -
PCR - 2 protocols for the two conditions (n = 5)
1 NF 1 Markers + mutation Aniridia Markers + mutation 1 9 2 4 F 2 -
C 2 + Healthy boy, no
genetic analysis
Continued
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Table II Continued:
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9 Alpers
syndrome
Markers + mutation MELAS Mutation
% ∗
1 6 2 4 F 1 + Healthy boy
CarrierAlpers,
no MELAS
C 1 + Healthy girl
No carrier Alpers,
no MELAS
10 HBOC Markers MELAS Mutation
% ∗
1 7 2 1 F 1 -
2 8 2 4 C 1 -
C 1 -
20 HME 1 Markers + mutation XL Retinitis
Pigmentosa
Markers 1 8 2 2 F 1 + Healthy boy
no genetic analysis
29 HBOC Markers Lujan-Fryns
syndrome
Markers 1 5 2 2 F 1 -
PCR + FISH - 2 protocols (n = 1)
6 DM1 Markers + repeat 22q11.2
deletion
FISH 1 Overstim.
2 Overstim.
3 4 2 0
4 10 2 3 F 1 -
FISH, fluorescence in situ hybridization; Array Comparative Genemoic Analysis; Nr., number; ins., insufficient; mut., mutation load s. indicates ‘syndrome’; XL indicates ‘X-Linked’;
NF 1, neurofibromatosis type 1; HME, hereditary multiple exostoses; HBOC, hereditary breast and ovarian cancer; AOA 1, ataxia-oculomotor apraxia type 1; SMA1, spinal muscular
atrophy type 1 ; Alpers., Alpers syndrome; MELAS, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; Lujan–Fryns s., Lujan–Fryns syndrome.
∗The amplification conditions for the mitochondrial MELAS mutation were as described in Sallevelt, et al. (2013) with a mutational threshold set on <15%.
less serious conditions. As we have suggested elsewhere (Dondorp
and De Wert, 2019), a possible example is cleidocranial dysostosis
(CCD), an autosomal dominant skeletal spectrum disorder involving
bone deformities (collarbone, skull) and abnormal teeth (Machol et al.,
2017). While this disorder comes with a high penetrance, the clinical
features are relatively mild. As CCD only moderately affects the quality
of life in most patients, it seems that a ‘stand alone’ PGT-M procedure
for this disorder would be at odds with the ‘high risk of a serious
disorder’ standard. However, should the applicants have an indication
for IVF or ICSI as fertility treatment, or if they are already having PGT
for an accepted (M/SR) indication, holding on to that same standard
would seem too strict.
Transfer decisions after cPGT-M/SR
According to a classical rule of PGT-practice, ‘affected embryos’
(meaning, embryos with the very mutation or abnormality targeted
in PGT-M/SR), should not be transferred to the womb (Thornhill et
al., 2005). An important argument for this is that in medically assisted
reproduction, professionals should take account of the welfare of the
child that they are causally involved in creating (Pennings et al., 2007).
As pointed out by ESHRE, there is a broad international consensus
that requests for reproductive assistance should not be granted if
chances are high that the resulting child will have a seriously diminished
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Figure 2 Legislation limiting the scope of acceptable PGT-
M/SR indications.
quality of life. However, for this to lead to the ‘do-not-transfer’ rule,
it must be the case that PGT-M/SR is only done for conditions that
clearly fall in the range of ‘high risk and serious’. Given that in the past
decennium, the scope of accepted indications has widened beyond the
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limited range of classical disorders to also include conditions marked
by a less than complete penetrance, a later time of onset, and at
least some treatment or surveillance options (e.g. hereditary breast
and ovary cancer (HBOC) or hypertrophic cardiomyopathy), it has
become less obvious that the ‘do-not-transfer’ rule would not allow
for exceptions. In a recent focus group study about professional views
about these issues, some participants said requests for transferring
affected embryos were difficult to swallow. In their view, such requests
signalled a capricious attitude on the part of the couple, out of tune
with professional efforts to help them avoid the reproductive risk
for which they had PGT in the first place. However, others regarded
such requests more favorably as an understandable adjustment of
priorities in the light of a reassessment of what is realistically feasible
(Soto Lafontaine et al., 2018). This, they said, was especially
understandable in cases where no further hormone stimulation cycles
were realistically possible and where, because of their fertility problem,
the alternative option of natural reproduction was not available to
the couple. When in such cases the only otherwise good quality
embryos available happen to be affected, these represent the couple’s
last chance to have a genetically related child. In the UK, regulations
allow considering such last chance affected embryos for transfer at
the patients request, but permission is required from a clinical ethics
committee on a case-by-case basis (Human Fertilisation & Embryology
Authority, 2019). This has been done for example for BRCA1 carrier
embryos.
Assuming, for the sake of debate, that cPGT-M/SR is offered to
couples that are normally fertile, it would seem that talk of ‘last
chance embryos’ does not apply. However, this impression is mistaken,
especially with regard to those couples who distinguish between a
primary and a secondary condition in terms of perceived severity.
Faced with the message that no embryos free of either condition are
found, then in cases where trying a further hormone-stimulation cycle
is not an option, they may request the transfer of embryos affected
by what in their view is the secondary target condition. These are
‘last chance embryos’ in the wider sense of enabling the couple to
start a pregnancy with the confidence that the resulting child will not
be affected by the disorder that they want to avoid most. Clearly,
making this request entails accepting that the child has a high chance of
developing the secondary condition, the one that they had preferred
to be able to avoid as well, albeit with a lower priority. Allowing
cPGT-M/SR may thus lead to an increased number of requests for
transferring affected embryos.
Discussion
Clinical feasibility
We report 40 applications for cPGT-M/SR. Sixteen couples started
their treatment. Thirty-nine IVF cycles led to the analysis of 187
embryos and 28 embryo transfers, resulting in five healthy children.
Pregnancy rate per transfer was 21%. This is in line with the fig-
ure reported by the PGT-consortium (Harper et al., 2012). In half
of the started cycles, we could at least identify one embryo suit-
able for transfer. Our results clearly demonstrate the feasibility of
cPGT-M/SR.
Bearing these results in mind, we expect an even better outcome
after full implementation of comprehensive methods as SNP or NGS-
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based haplotyping that allow simultaneous testing for an unlimited
number of genetic disorders hence avoiding multiple biopsies.
Scope for wider indications setting
In the experience of our centre with cPGT-M/SR, a large percentage
of couples distinguished between a primary and secondary condition
in terms of perceived relative seriousness. However, no cases were
listed where the secondary condition would not on its own have met
the ‘high risk of a serious condition’ standard. The lack of requests
for cPGT involving a mild condition as secondary to an accepted
PGT-M/SR condition is not surprising, given that the Dutch ‘PGD
regulations’ strictly adhere to the ‘high risk of a serious condition’
standard and do not recognize—or even discuss—the case for making
an exception for applications with an altered proportionality profile
(Tweede Kamer der Staten Generaal, 2009). If ESHRE’s reasoning on
this point is sound, as we think it is, this may have as a consequence
that in the Netherlands and other countries that also fail to allow for
this exception, some are denied without a good reason what might
have been a meaningful option for them. However, an important
qualification is that the reasoning behind accepting a lower standard
is only valid as long as a further hormone stimulation cycle would not
be needed in order to successfully complete a cPGT procedure. While
trying a further cycle may be necessary to obtain transferable embryos
not also affected by the secondary target condition, this inevitably
comes with the full array of burdens, risks and (moral) costs of regular
PGT-M/SR. For this to be acceptable in terms of the ‘high risk of a
serious disorder’ standard, the secondary condition would have to be
sufficiently high risk and serious to qualify as a PGT indication on its
own (Dondorp and De Wert 2019). Clearly, in countries upholding
this standard, making exceptions for cPGT cases requires adequately
informing the applicants about this qualification as part of pre-test
counselling.
Requests for transferring affected embryos:
three categories
There are three types of situation in which professionals may be
confronted with requests to transfer affected last chance embryos
in cPGT-M/SR (Dondorp and De Wert 2019). At one end of the
spectrum, one may think of cases where, notwithstanding a possible
categorization by the applicants in terms of primary and secondary,
both conditions are evidently highly serious. In our view, transferring
embryos leading to disorders in this category would be difficult to
reconcile with the responsibility of professionals to take account of
the welfare of the child-to-be. Using an example from the list of cPGT-
M/SR cases in our centre (Table I), a potential request by couple #25 to
transfer any last chance embryos that would lead to a child with either
ataxia with oculomotor apraxia type 1 (AOA1) or spinal muscular
atrophy type 1 (SMA1) should be rejected. This scenario is theoretical
in so far as couples are not likely to ask for the transfer of affected
embryos in such cases.
At the opposite end are cases where the secondary condition is
clearly not ‘high risk and serious’, whereas the primary condition is.
If, following the reasoning by ESHRE, cPGT-M/SR is allowed for such
cases, this may lead to requests for transferring affected last chance
embryos that professionals have no good reason to reject, given that
such a transfer would not involve a high risk of a child with a seriously
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diminished quality of life. Here again, CCD might be an example of such
a secondary condition. In such cases, a problem would rather arise with
couples requesting an additional hormone stimulation cycle as a further
attempt to obtain transferrable embryos not affected by the secondary
condition. As explained in the previous section, such a further attempt
would bring the proportionality balance back into to the range where
the ‘high risk of a serious condition’ standard would seem to exclude
conditions such as CCD.
Probably the most difficult cases fall in the middle of the spectrum.
These comprise requests for transferring last chance embryos where
the secondary condition, although an accepted indication, is in the grey
area where it can be a matter of debate if the condition qualifies as
‘high risk and serious’. As an example, one may think here of BRCA-
mutations in female fetuses. As these conditions have been subject to
quite some discussion about whether they would qualify as acceptable
indications under the ‘high risk of a serious condition’ standard, it is
not obvious what the response should be with regard to requests for
transferring ‘last chance’ embryos affected with one of those condi-
tions (Dondorp and De Wert, 2019). We propose shared decision-
making about such ‘grey area’ cases, in which the particular views of
the applicants and the history and context of their experiences with the
condition (‘the story behind the request’; Soto Lafontaine et al. 2018)
are taken into account. The one case (couple #14) where last chance
embryos affected with Peutz–Jeghers syndrome were transferred on
request from a couple having cPGT-M, can perhaps be argued to fall in
this middle category.
Scope for reverting to single condition
PGT-M/SR
Our conclusion with regard to the first type of cases entails that the
couple may end up empty-handed. A possible way out in these cases
is to go ahead with a new cycle for one condition only (the condition
regarded as primary by the couple). While this would involve a 25–
50% chance of embryos with the secondary condition being trans-
ferred (in monogenic disorders), professionals (and couples) may feel
more comfortable with this alternative as compared with transferring
embryos known to be affected. However, in cases with two fully
penetrant conditions that are both in the higher range of seriousness,
it can be questioned whether testing for just one of those conditions
is ethically acceptable, given that a 25 or 50% transmission risk would
still amount to a high risk of a child with a seriously diminished quality
of life. Ethically, this is similar to doing ‘just IVF’ when an infertile
couple is known to be at a high risk of having a child with a serious
disorder (Dondorp and De Wert, 2019). Some centres may find this
acceptable on the condition of a clearly indicated intention on the
part of the couple to make use of PNT and ask for a termination in
case the fetus turns out to be affected (De Wert et al., 2014). Of
course, any such understandings about further reproductive decision-
making are a matter of trust that cannot be enforced. However,
they do relieve professionals from a co-responsibility for the welfare
of a seriously affected child that might be born as a result of the
couple’s backtracking on what was agreed at the pre-treatment stage
(Pennings et al., 2003). In cases where the secondary condition is
more in a grey-area of risk and seriousness, reverting to PGT-M/SR
for the primary condition only may well be acceptable. But if so,
solving the dilemma through transferring embryos affected with that
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grey-area condition, if that is the couple’s request, should perhaps be
regarded as acceptable as well, also because that would avoid a further
cycle with its burdens and costs. It is important that centre-policies
with regard to such choices are clearly defined and timely discussed
with the couple.
Timely information and counselling
Our data and our analysis underscore the importance of timely infor-
mation and counselling regarding all relevant aspects of cPGT-M/SR.
This includes the inevitably lower number of embryos suitable for
transfer, also in the light of other risk factors reducing success rate, such
as maternal age. Other options than cPGT-M/SR for both conditions
may need to be considered. In addition to the possibility of PGT for one
condition and offering PNT for the other, the use of donor gametes to
exclude the genetic burden in one of the parents may be an acceptable
option for the couple. Moreover, the applicants should be informed
already at the pre-test stage of centre policies with regard to the
ethically laden choices that may emerge in the process of cPGT-M/SR.
This should also include information about the scope for allowing the
applicants a change of mind during later stages of the procedure.
The one case in our centre where affected embryos were eventually
transferred (couple #14), involved strained decision-making at a later
stage where professionals had wrongly assumed that there was a clear
understanding with the couple that they did not want embryos with
either condition to be transferred.
Concluding remarks and recommendations
(i) cPGT-M/SR is feasible.
(ii) cPGT-M/SR should be discussed as a possible treatment option
with couples at high risk for offspring with more than one genetic
condition.
(iii) Couples applying for cPGT-M/SR should be informed at the
stage of pre-treatment informed consent that this procedure entails
a lower chance of success than PGT for one condition, and an even
further decrease of chances of pregnancy. Pre-test counselling should
include a discussion of the couple’s views with regard to the relative
importance of preventing the birth of a child with either condition. Do
they think of those conditions in terms of primary and secondary?
(iv) In countries where PGT-M/SR is only allowed for couples at
a high risk of transmitting a serious disorder, this currently limits
the scope for the conditions that can be accepted as a secondary
condition. However, to the extent that cPGT-M/SR involves an altered
proportionality balance, a case can be made for allowing secondary
conditions of lower risk and seriousness also in those countries.
(v) Centres allowing cPGT-M/SR may be confronted with requests
for transferring embryos affected with what the couple regards as the
secondary condition. It is important to have a proactive discussion of
all possible outcomes already at the stage of pre-treatment informed
consent. This discussion should include the policy of the centre with
regard to dealing with such transfer requests. This may lead to a couple-
specific proposal for ranking embryos for transfer that takes account of
the couple’s preferences as well as of the limits to acceptable transfers
set by the centre. As we have discussed, professionals should not go
ahead with requests for transferring an embryo where there is a high
chance of this leading to a child with a seriously diminished quality
of life.
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(vi) Couples may change their minds with regard to the priority
of their preferences during the cPGT-M/SR procedure. A patient-
centred policy would require professionals to allow for this as much
as reasonably possible, while clearly explaining the inevitable limits
to this.
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